Gastric inhibitory polypeptide/glucagon like peptide 1 co-agonist peptide II - Eli Lilly and Company
Alternative Names: GIP/GLP Coagonist Peptide II - Eli Lilly and Company; GIP/GLP-1 coagonist II - Eli Lilly and Company; GIP/GLP-1 coagonist peptide II - Eli Lilly and CompanyLatest Information Update: 23 Aug 2023
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics; Peptides
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 08 Aug 2023 Discontinued - Phase-I for Diabetes mellitus in USA (Parenteral) (Eli Lilly and Company pipeline, August 2023)
- 06 May 2022 Gastric inhibitory polypeptide/glucagon like peptide 1 co-agonist peptide II is still in phase I trials for Diabetes mellitus in USA (Eli Lilly and Company pipeline, May 2022)
- 07 Oct 2021 Discontinued - Phase-I for Diabetes mellitus in USA, prior to October 2021 (Parenteral)